drugset / Trial / NCT04776525

Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

NCT04776525 ↗

NaSingle-groupOpen-labelTreatment

Summary

Nearly half of patients with high-grade, localized soft tissue sarcoma (STS) of extremities and trunk wall develop disease recurrence after local therapy. Adjuvant chemotherapy with ifosfamide and doxorubicin may improve long-term disease-free survival, but the benefit of adjuvant treatment is limited and predictive factors for treatment response are lacking. The aim of this study is to explore sequential treatment with ifosfamide and doxorubicin in a neoadjuvant setting and to investigate biomarkers predictive of treatment response.

Timeline

Start
2021-04-27
Primary completion
2026-09
Completion
2036-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 80 mg/m2 —
Subject Ifosfamide Small molecule 3000 mg/m2 —

Indications